We are focused on developing cellular therapy for chronic aging-related diseases, and other life-threatening conditions, for which there is a clear unmet medical need.
Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community to treat disease and improve patient healthspan.
Our therapeutic indications currently under clinical study are:
• Hypoplastic Left Heart Syndrome
• Alzheimer’s Disease
• Aging Frailty
Lomecel-B is not an approved treatment product in the United States, and is considered an investigational therapeutic. Participation in clinical trials is ongoing and provides opportunity for patient involvement. We invite you to learn more about the clinical trials in various stages of completion or currently enrolling.
We sponsor a Treatment Registry Trial in The Bahamas under the approval and authority of the National Stem Cell Ethics Committee (NSCEC). Eligible participants for the Registry may receive Lomecel-B at their own expense at one of two private partner clinics in Nassau for NSCEC-approved indications: Frailty, mild cognitive impairment, Alzheimer’s Disease and related dementias, and osteoarthritis. Lomecel-B is not an approved product in The Bahamas or the United States, and is considered an investigational therapeutic. For more information about this program please contact us.
Click here to replay our KOL event, which was held on August 16, 2023, featuring Sunjay Kaushal, MD, PhD and Ram Kumar Subramanyan, MD, PhD, discussing the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, to improve the outcome for Hypoplastic Left Heart Syndrome (HLHS) patients.
Click Here to Watch the Replay